Dr. med. Ursula Hasler-Strub
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Gennari A, Bernhard J, Morales S, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, von Moos R, Cortes J, Vidal M, Hennessy B, Jerusalem G. A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Ann Oncol 2017
Dec 8, 2017A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
Dec 8, 2017Ann Oncol 2017
Gennari A, Bernhard J, Morales S Murillo, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan M M, Ribi K, Amillano Parraga K, Walshe J, Sun Z, Hasler-Strub Ursula, Colleoni M, Kennedy M J, von Moos R, Cortes J, Vidal M J, Hennessy B, Jerusalem G
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Zaman K, Rondeau S, Hawle H, Rudolf C, Perey L, Wiliders H, Berset C, Mueller A, Rochlitz C, Hasler-Strub U, Mamot C, Winterhalder R, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015; 51:1212-20.
Apr 16, 2015Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Apr 16, 2015Eur J Cancer 2015; 51:1212-20
Zaman Khalil, Rondeau Stephanie, Hawle Hanne, Rudolf Christine Biaggi, Perey Lucien, Wiliders Hans, Berset Catherine, Mueller Andreas, Rochlitz Christoph, Hasler-Strub Ursula, Mamot Christoph, Winterhalder Ralph, Neven Patrick
[Breast cancer: screening, treatment and follow-up]
Hasler-Strub U, Moos R. [Breast cancer: screening, treatment and follow-up]. Praxis (Bern 1994) 2010; 99:413-8.
Mar 31, 2010[Breast cancer: screening, treatment and follow-up]
Mar 31, 2010Praxis (Bern 1994) 2010; 99:413-8
Hasler-Strub Ursula, Moos R von
Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis
Hess B, Hasler-Strub U, Ackermann D, Jaeger P. Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 1997; 12:1362-8.
Jul 1, 1997Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis
Jul 1, 1997Nephrol Dial Transplant 1997; 12:1362-8
Hess B, Hasler-Strub Ursula, Ackermann D, Jaeger P